Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH-302 and Sunitinib in Treatment-naïve Metastatic Pancreatic Neuroendocrine Tumors
NCT02402062Phase 2Completed
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- May 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of evofosfamide in Pancreatic neuroendocrine tumor (PanNET), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoint: Objective Response Rate at 36 months. Started May 2015; status: completed.
02
Drugs
evofosfamide
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02402062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02402062.